about
Prion pathogenesis in the absence of NLRP3/ASC inflammasomesThe prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6The Priority position paper: Protecting Europe's food chain from prionsEfficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture.Prion protein and Abeta-related synaptic toxicity impairment.Structure-based drug design identifies polythiophenes as antiprion compounds.The role of the NADPH oxidase NOX2 in prion pathogenesis.Cystatin F is a biomarker of prion pathogenesis in mice.Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling.The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science.The workings of the amyloid diseases.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.A neuroprotective role for microglia in prion diseases.SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells.Cells and prions: a license to replicate.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.The immunobiology of prion diseases.Systemic amyloidosis: novel therapies and role of biomarkers.Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice.Efficient amyloid A clearance in the absence of immunoglobulins and complement factors.Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney.Extended characterization of the novel co-isogenic C57BL/6J Prnp-/- mouse line.Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patientsSalvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomideIdentification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and UrineTreatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosisRegulated expression of amyloidogenic immunoglobulin light chains in micePrognostication of survival and progression to dialysis in AA amyloidosisUrinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosisPatterns of relapse after upfront bortezomib therapy in AL amyloidosisSeverity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete responsePrion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrierSimple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients
P50
Q27316552-67ED93D6-471C-45B4-865B-5D5A8D6CB438Q28511844-5007E6BC-280B-4F6F-8E91-F2DC6FB05576Q28830533-BAAA5C71-63F8-495D-AF6B-1156BE0BD029Q33786911-3088FF80-D145-40CE-B729-88B525581AABQ34233877-9B3DC538-DB65-478A-ABAE-72539C665AE5Q34488418-77E6BEAD-E3AA-4A3F-9DE9-869E65430394Q34682177-778E4E1B-E5F7-4EA3-A694-2D5C035BC0CCQ36274319-0C628978-1214-4482-A447-10F117CBDC19Q36381643-B3FDDDA6-2D7B-4529-896B-35F493735E88Q36600160-748F749E-30C4-4B45-A368-12F6B4431123Q36745030-9F6A9032-1FA9-4830-B5F0-D910028BF9EBQ36801112-7AD68934-CD57-4EF5-9296-A28496D5EC28Q36862339-9216B482-BD24-42E9-AB00-422365BA7212Q36949886-27085658-1E1E-4810-8904-3CB6E1481793Q37322155-BD721E6B-5FEE-4ABD-9A9E-8FF5119458BFQ37520006-D1ACE18E-DA79-4E7E-BAD8-6B5BC3E4DE9BQ37676296-C5E2EA52-02E9-442F-9E90-9D3B3F5C982CQ38159911-A2B08FC3-CFF4-4509-907E-E901BF652170Q38829923-C64D1C40-F199-405A-B035-32807F5858E6Q43173689-B25BD431-6EFA-4998-A690-F7A396DD7595Q44519802-507372E8-501D-4326-AEF5-89960C662449Q46380099-4A4C5EA2-1A0E-466C-81A5-3AF8A4DA06A0Q51039671-E0B1A01C-A67E-438E-8CA7-432C80522773Q51573728-0CCB7B9C-76AC-42AC-8FCB-D0B6156CC03AQ53339449-FCB6812D-30B2-4F83-A666-D4947C19E650Q53988051-A803E2CC-A888-45D1-819F-854205C0431EQ58029880-A3DBB8E2-4DD5-4DE4-8AE6-240E516751F6Q58030111-8484D7F6-C41A-479A-B689-947CE5829DC9Q58030328-09DD6E87-189C-4953-8619-0685CA10C27FQ58030485-407A35A0-BE04-4FCD-A0D6-0061877E451CQ58270563-8F6644A5-E3E0-4380-AB66-E7FDE26D80E1Q58289419-F31BA2B4-CF3D-4FE0-B246-CBC152107317Q58293086-237474F2-45F7-487B-A28E-3D50A6AB7F94Q58424126-C7FA9FC7-ADC3-4706-BAAF-999179A47295Q58424130-48C8E147-0032-4155-B589-E83B1D257CB0Q60049338-043B4AA6-2321-4007-8642-2A295BB3B93EQ92570522-25D083D4-0E3F-4320-AE83-22D56EC53E0E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mario Nuvolone
@an
Mario Nuvolone
@ast
Mario Nuvolone
@br
Mario Nuvolone
@ca
Mario Nuvolone
@co
Mario Nuvolone
@da
Mario Nuvolone
@de
Mario Nuvolone
@en
Mario Nuvolone
@es
Mario Nuvolone
@eu
type
label
Mario Nuvolone
@an
Mario Nuvolone
@ast
Mario Nuvolone
@br
Mario Nuvolone
@ca
Mario Nuvolone
@co
Mario Nuvolone
@da
Mario Nuvolone
@de
Mario Nuvolone
@en
Mario Nuvolone
@es
Mario Nuvolone
@eu
prefLabel
Mario Nuvolone
@an
Mario Nuvolone
@ast
Mario Nuvolone
@br
Mario Nuvolone
@ca
Mario Nuvolone
@co
Mario Nuvolone
@da
Mario Nuvolone
@de
Mario Nuvolone
@en
Mario Nuvolone
@es
Mario Nuvolone
@eu
P1053
K-4763-2018
P106
P1153
14039439100
P21
P31
P496
0000-0001-8334-1684